Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1401 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 21
1402 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Denmark 65
1403 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Romania 25
1404 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 27
1405 Apheresis Allogeneic Polycythaemia Vera Hematology 2025 Standard Therapy Germany 61
1406 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 25
1407 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 51
1408 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 70
1409 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 53
1410 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 61
1411 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russian Federation 49
1412 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 36
1413 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 62
1414 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 54
1415 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 74
1416 Apheresis Allogeneic NHL Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 49
1417 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 62
1418 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 74
1419 Apheresis Allogeneic NHL Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Argentine 57
1420 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 56
1421 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 71
1422 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Spain 59
1423 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 65
1424 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 14
1425 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Denmark 57
1426 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
1427 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 51
1428 Apheresis Allogeneic Richter Transformation CDLBCC Hematology 2025 Standard Therapy Germany 68
1429 Apheresis Allogeneic Acute Myelogenous Leukemia-MR Hematology 2025 Standard Therapy Russian Federation 16
1430 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
1431 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 66
1432 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 50
1433 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 38
1434 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 43
1435 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
1436 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 51
1437 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 59
1438 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 66
1439 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
1440 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 33
1441 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 48
1442 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Netherlands 66
1443 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 57
1444 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 56
1445 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1446 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 24
1447 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 61
1448 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1449 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 53
1450 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 62
1451 Apheresis Autologous Mantle Cell Lymphoma Hematology 2025 Standard Therapy Germany 45
1452 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 61
1453 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 32
1454 Apheresis Autologous Diffuse Large B-Cell Lymphoma Hematology 2025 Standard Therapy Germany 62
1455 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 75
1456 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 70
1457 Cord Tissue Autologous Autism Neurology 2024 Experimental Therapy Romania 6
1458 Cord Tissue Allogeneic – Related Autism Neurology 2024 Experimental Therapy Romania 6
1459 Cord Tissue Autologous Autism Neurology 2024 Experimental Therapy Romania 4
1460 Cord Tissue Allogeneic – Related Autism Neurology 2024 Experimental Therapy Romania 6
1461 Cord Tissue Allogeneic – Unrelated Degenerative and Traumatic Cartilage Orthopedics 2024 Experimental Therapy Poland 50,3
1462 Cord Tissue Allogeneic – Unrelated Degenerative and Traumatic Cartilage Orthopedics 2024 Experimental Therapy Poland 49,5
1463 Cord Tissue Allogeneic – Unrelated Degenerative and Traumatic Cartilage Orthopedics 2024 Experimental Therapy Poland 58,11
1464 Cord Tissue Allogeneic – Unrelated Graft Versus Host Disease Hematology 2024 Experimental Therapy Poland 7,7
1465 Cord Tissue Allogeneic – Unrelated Graft Versus Host Disease Hematology 2024 Experimental Therapy Poland 15,7
1466 Cord Tissue Allogeneic – Unrelated Ovarian Dysfunction Gynecology 2024 Experimental Therapy Poland 48,1
1467 Cord Tissue Allogeneic – Related Severe Pulmonary Hypertension +Mitral Regurgitation Cardiovascular/Pulmonary 2024 Experimental Therapy Romania 2,6
1468 Cord Tissue Allogeneic – Unrelated Amyotrophic lateral sclerosis Neurology 2024 Experimental Therapy Poland 57,6
1469 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2024 Experimental Therapy Poland 68,2
1470 Cord Tissue Allogeneic – Related Autism Neurology 2024 Experimental Therapy Romania 17
1471 Cord Tissue Autologous Autism Neurology 2024 Experimental Therapy Romania 7
1472 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2024 Experimental Therapy Poland 61,9
1473 Cord Tissue Allogeneic – Unrelated Degenerative and traumatic cartilage damage Orthopedics 2024 Experimental Therapy Poland 45,4
1474 Cord Tissue Allogeneic – Unrelated Amyotrophic lateral sclerosis Neurology 2024 Experimental Therapy Poland 56,9
1475 Cord Tissue Allogeneic – Unrelated Graft-versus-host disease Hematology 2024 Experimental Therapy Poland 0,10
1476 Cord Tissue Allogeneic – Unrelated Amyotrophic lateral sclerosis Neurology 2024 Experimental Therapy Poland 39,0
1477 Cord Tissue Allogeneic – Unrelated GvHD Neurology 2024 Experimental Therapy Poland 9,2
1478 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2024 Experimental Therapy Poland 5,11
1479 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2024 Experimental Therapy Poland 13,10
1480 Cord Tissue Allogeneic – Unrelated Leukodystrophy Neurology 2024 Experimental Therapy Poland 1,9
1481 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2024 Experimental Therapy Poland 7,11
1482 Cord Tissue Allogeneic – Unrelated Leukodystrophy Neurology 2024 Experimental Therapy Poland 1
1483 Cord Tissue Allogeneic – Unrelated Cerebellar-spinal ataxia Neurology 2024 Experimental Therapy Poland 35,5
1484 Cord Tissue Allogeneic – Unrelated Leukodystrophy Neurology 2024 Experimental Therapy Poland 1,9
1485 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2024 Experimental Therapy Poland 4,5
1486 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Romania 11
1487 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Romania 10
1488 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Romania 6
1489 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Romania 4
1490 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Romania 5
1491 Cord Blood Allogeneic Cerebral Palsy Neurology 2024 Experimental Therapy Poland 3,5
1492 Cord Blood Allogeneic Cerebral Palsy Neurology 2024 Experimental Therapy Poland 7,7
1493 Cord Blood Autologous CP Neurology 2024 Experimental Therapy Hungary 4
1494 Cord Blood Autologous Pervasive Developmental Disorder Neurology 2024 Experimental Therapy Poland 3,7
1495 Cord Blood Autologous Pervasive Developmental Disorder Neurology 2024 Experimental Therapy Poland 5,9
1496 Cord Blood Autologous Pervasive developmental disorder Neurology 2024 Experimental Therapy Poland 4,8
1497 Cord Blood Allogeneic – Related fanconi aplastic anemia Hematology 2024 Standard Therapy Turkey 12
1498 Cord Blood Autologous Neuroblastoma Neurology 2024 Standard Therapy Poland 4
1499 Cord Blood Autologous Pervasive developmental disorder Neurology 2024 Experimental Therapy Poland 9,9
1500 Cord Blood Autologous Autism Neurology 2024 Experimental Therapy Slovakia 4
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?